About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Entwistle & Cappucci LLP Announces It Has Filed a Securities Class Action Against Emergent BioSolutions Inc. (NYSE: EBS)

By: via Business Wire

Entwistle & Cappucci LLP (“Entwistle & Cappucci” or “E&C”) today announced that the firm has filed a securities class action lawsuit on behalf of investors that purchased Emergent BioSolutions Inc.(“Emergent” or the “Company”) (NYSE: EBS) common stock from April 24, 2020 through April 16, 2021, inclusive. A copy of the complaint is available at: www.entwistle-law.com. Institutions and individuals that invested in Emergent common stock may contact E&C for additional information concerning the litigation and to discuss potential strategies for the recovery of any losses.

The action arises from Emergent’s pervasive quality control problems at the Company’s Bayview COVID-19 vaccine manufacturing facility in Baltimore, Maryland that culminated in the destruction of up to 100 million COVID-19 Johnson & Johnson and AstraZeneca vaccine doses.

The complaint alleges, based on documents recently made public, that numerous statements issued by Emergent concerning its manufacturing processes, capabilities, quality control procedures and status as a purported leader in the biopharmaceutical industry were materially false and misleading.

  • First, an internal audit conducted in June 2020 by Johnson & Johnson subsidiary Janssen Pharmaceuticals found two “Major” quality control deficiencies, including “deficient” contamination controls and that the Company failed to conform to basic industry standards;
  • Second, U.S. Food and Drug Administration (“FDA”) inspections of Emergent’s Baltimore facility conducted both prior to and following the Company’s award of COVID-19 vaccine manufacturing contracts notified the Company of a “series of quality control shortcomings” including the “fail[ure] to ensure that electronic data” was “protected from deletion or manipulation,” “carelessness in the handling of rejected materials” and failure to “follow proper testing and lab procedures;” and
  • Third, Dr. Carlo de Notaristefani, an Operation Warp Speed Manufacturing & Supply Chain adviser charged with overseeing the production of COVID-19 vaccines on behalf of the federal government, issued a draft report in June 2020 highlighting Emergent’s key manufacturing risk as the “remediation of the compliance gaps identified by the FDA inspection held in April 2020.” Dr. Notaristefani further noted that the Company’s staffing was “inadequate to enable the Company to manufacture at the required rate” and Emergent would need to expend “significant resources” and “strengthen” quality controls to meet manufacturing scale-up and roll-out deadlines.

Emergent allegedly admitted to the FDA – but not the investing public – that the Company was plagued with known manufacturing problems, including that the “sudden scale-up” had “strained the capacity” of the Company’s COVID-19 vaccine manufacturing facility.

When these facts became public through a series of partial corrective disclosures, the price of Emergent’s common stock declined significantly, eliminating over $1.5 billion in market capitalization.

If you invested in Emergent BioSolutions common stock, please feel free to contact attorneys Robert N. Cappucci or Joshua K. Porter at 212-894-7200, or via e-mail at rcappucci@entwistle-law.com or jporter@entwistle-law.com.

About Entwistle & Cappucci

Entwistle & Cappucci is a national law firm providing exceptional legal representation to clients globally in the most complex and challenging legal matters. Our practice encompasses all areas of litigation, including securities, antitrust, corporate transactions, general corporate and commercial, creditor’s rights and bankruptcy, corporate governance and fiduciary duty, government affairs, insurance, investigations and white-collar defense. Our clients include public and private corporations, major hedge funds, public pension funds, governmental entities, leading institutional investors, domestic and foreign financial services companies, emerging business enterprises and individual entrepreneurs.

Contacts

More News

View More
3 Dividend Aristocrats to Buy Before Year’s End
Via MarketBeat
Tickers ADM CTAS PEP
Why Semtech Stock Is Rallying After Its NVIDIA Setback
Via MarketBeat
Tickers NVDA SMTC
SharkNinja Is Flashing a Buy Signal the Market Is Ignoring
Via MarketBeat
Tickers SN
When Downgrades Create Opportunities: 3 Stocks to Watch Now
Via MarketBeat
Topics Artificial Intelligence Government
Tickers ACN CRM CRWD
3 REITs to Watch as Rate Cuts Ignite a Real Estate Super Cycle
Via MarketBeat
Tickers CPT EQR O
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.